Argitalpenak (74) Margarita Sanchez del Río González argitalpenak

2024

  1. Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey

    Journal of Headache and Pain, Vol. 25, Núm. 1

2023

  1. Consensus about monoclonal antibodies in migraine of the Headache Study Group of the Madrid Association of Neurology

    Kranion, Vol. 18, Núm. 1, pp. 5-20

  2. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline

    Journal of Headache and Pain, Vol. 24, Núm. 1

  3. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 2: flunarizine

    Journal of Headache and Pain, Vol. 24, Núm. 1

  4. European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – part 3: topiramate

    Journal of Headache and Pain, Vol. 24, Núm. 1

  5. Pathophysiology of migraine aura

    Handbook of Clinical Neurology (Elsevier B.V.), pp. 71-83

  6. The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside

    Nature Reviews Neurology, Vol. 19, Núm. 8, pp. 489-505

  7. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis

    Journal of Headache and Pain, Vol. 24, Núm. 1

2022

  1. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  2. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure

    The journal of headache and pain, Vol. 23, Núm. 1, pp. 133

  3. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

    Journal of Headache and Pain, Vol. 23, Núm. 1

2021

  1. Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

    Advances in Therapy, Vol. 38, Núm. 8, pp. 4442-4460

  2. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance

    Journal of Headache and Pain, Vol. 22, Núm. 1

  3. Document of revision and updating of medication overuse headache (MOH)

    Neurologia, Vol. 36, Núm. 3, pp. 229-240

  4. The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish

    Headache, Vol. 61, Núm. 9, pp. 1403-1410

2020

  1. Cluster headache therapies: pharmacology and mode of action

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 6, pp. 641-654

  2. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study

    European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108

  3. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578

  4. The potential of lasmiditan in migraine

    Therapeutic Advances in Neurological Disorders, Vol. 13

2019

  1. Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice

    Neurologia, Vol. 34, Núm. 6, pp. 408-417